BACKGROUNDResearch and Commercialization Agreement • January 26th, 2000 • Medarex Inc • Biological products, (no disgnostic substances) • California
RESEARCH AND COMMERCIALIZATION AGREEMENTResearch and Commercialization Agreement • September 22nd, 2004 • Celldex Therapeutics Inc • Biological products, (no disgnostic substances) • New Jersey
This Research and Commercialization Agreement (the “Agreement”), effective as of April 6, 2004 (the “Effective Date”), is entered by and between Medarex, Inc., a New Jersey corporation, with a principal place of business at 707 State Road, Princeton, New Jersey 08540, GenPharm International, Inc., a wholly owned subsidiary of Medarex, Inc., (collectively, “Medarex”), and Celldex Therapeutics, Inc., a Delaware corporation, with a principal place of business at 519 Route 173 W, Bloomsbury, New Jersey 08804 (“Celldex”).
AMENDED AND RESTATEDResearch and Commercialization Agreement • June 2nd, 2000 • Curis Inc • Biological products, (no disgnostic substances) • Massachusetts
EX-10.21 39 d720189dex1021.htm EX-10.21 CONFIDENTIAL RESEARCH AND COMMERCIALIZATION AGREEMENTResearch and Commercialization Agreement • May 5th, 2020 • California
THIS RESEARCH AND COMMERCIALIZATION AGREEMENT (the “Agreement”), effective as of July 9, 1998, is entered by and between GenPharm International, Inc., a wholly owned subsidiary of Medarex, Inc., and Medarex, Inc., a New Jersey corporation, with a principal place of business at 1545 Route 22 East, Annandale, New Jersey 08801 (together “Medarex”), and FibroGen, Inc. and its wholly-owned subsidiary, FibroPharma, Inc., with a principal place of business at 225 Gateway Boulevard, South San Francisco, California 94080 (together “FibroGen”).
EX-10.23 41 d720189dex1023.htm EX-10.23 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities...Research and Commercialization Agreement • May 5th, 2020
THIS AMENDMENT NO. 2 TO RESEARCH AND COMMERCIALIZATION AGREEMENT (“Amendment”) is made and entered into effective as of January 28, 2002 (the “Amendment Date”) by and between MEDAREX, INC., 707 State Road, Suite 206, Princeton, NJ 08540, GENPHARM INTERNATIONAL INC., a wholly-owned subsidiary of Medarex, Inc. (together, “Medarex”), and FibroGen, Inc., a Delaware corporation, 225 Gateway Boulevard, South San Francisco, California 94080 and FIBROPHARMA, INC., a wholly-owned subsidiary of FIBROGEN, INC. (collectively, “FibroGen”). Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same meanings as such terms are defined in the Agreement (as defined below).
RESEARCH AND COMMERCIALIZATION AGREEMENTResearch and Commercialization Agreement • January 18th, 2008 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • New Jersey
THIS RESEARCH AND COMMERCIALIZATION AGREEMENT (the “Agreement”), effective as of April 6, 2004 (the “Effective Date”), is entered by and between MEDAREX, INC., a New Jersey corporation, with a principal place of business at 707 State Road, Princeton, New Jersey 08540, GENPHARM INTERNATIONAL, INC., a wholly owned subsidiary of Medarex, Inc., (collectively, “Medarex”), and CELLDEX THERAPEUTICS, INC., a Delaware corporation, with a principal place of business at 519 Route 173 W, Bloomsbury, New Jersey 08804 (“Celldex”).
AMENDMENT NO. 1 TO RESEARCH AND COMMERCIALIZATION AGREEMENTResearch and Commercialization Agreement • June 11th, 2014 • Fibrogen Inc • Pharmaceutical preparations
THIS AMENDMENT No. 1 TO RESEARCH AND COMMERCIALIZATION AGREEMENT (“Amendment”) is made and entered into effective as of June 30, 2001 (the “Amendment Date”) by and between MEDAREX, INC., 707 State Road, Suite 206, Princeton, NJ 08540, GENPHARM INTERNATIONAL INC., a wholly-owned subsidiary of Medarex, Inc. (together, “Medarex”), and FIBROGEN, INC., a Delaware corporation, 225 Gateway Boulevard, South San Francisco, California 94080 and FIBROPHARMA, INC., a wholly-owned subsidiary of Fibrogen, Inc. (collectively, “FibroGen”). Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same meanings as such terms are defined in the Agreement (as defined below).
AMENDMENT NO. 2 TO RESEARCH AND COMMERCIALIZATION AGREEMENTResearch and Commercialization Agreement • November 5th, 2020 • Fibrogen Inc • Pharmaceutical preparations
This Amendment No. 2 to research and commercialization Agreement ("Amendment") is made and entered into effective as of January 28, 2002 (the "Amendment Date") by and between Medarex, Inc., 707 State Road, Suite 206, Princeton, NJ 08540, GenPharm International Inc., a wholly-owned subsidiary of Medarex, Inc. (together, "Medarex"), and FibroGen, Inc., a Delaware corporation, 225 Gateway Boulevard, South San Francisco, California 94080 and FibroPharma, Inc., a wholly-owned subsidiary of FibroGen, Inc. (collectively, "FibroGen"). Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same meanings as such terms are defined in the Agreement (as defined below).
